Based on the key indicators related to EXACT Sciences' liquidity, profitability, solvency, and operating efficiency, EXACT Sciences is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December. At this time, EXACT Sciences' Other Stockholder Equity is comparatively stable compared to the past year. Total Liabilities is likely to gain to about 3.5 B in 2024, despite the fact that Retained Earnings Total Equity is likely to grow to (2.8 B). Key indicators impacting EXACT Sciences' financial strength include:
Investors should never underestimate EXACT Sciences' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor EXACT Sciences' cash flow, debt, and profitability to make informed and accurate decisions about investing in EXACT Sciences.
Net Income
(214.36 Million)
EXACT
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Average Payables
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Change In Cash
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change To Liabilities
Sale Purchase Of Stock
Stock Based Compensation
Total Cashflows From Investing Activities
Other Cashflows From Investing Activities
Change To Inventory
Investments
Dividends Paid
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Change To Account Receivables
Change To Netincome
Net Borrowings
Change Receivables
Change To Operating Activities
Exchange Rate Changes
Total Assets
Total Stockholder Equity
Net Debt
Cash
Other Assets
Cash And Short Term Investments
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Other Stockholder Equity
Total Liab
Total Current Assets
Other Current Liab
Total Current Liabilities
Property Plant And Equipment Net
Retained Earnings
Accounts Payable
Non Current Assets Total
Non Currrent Assets Other
Common Stock Total Equity
Other Current Assets
Property Plant And Equipment Gross
Accumulated Other Comprehensive Income
Common Stock
Intangible Assets
Property Plant Equipment
Good Will
Other Liab
Short Term Investments
Non Current Liabilities Total
Current Deferred Revenue
Short Long Term Debt Total
Long Term Debt
Net Tangible Assets
Retained Earnings Total Equity
Long Term Debt Total
Capital Surpluse
Inventory
Non Current Liabilities Other
Accumulated Depreciation
Short Term Debt
Net Receivables
Short Long Term Debt
Net Invested Capital
Net Working Capital
Capital Stock
Capital Lease Obligations
Interest Expense
Other Operating Expenses
Operating Income
Ebit
Research Development
Ebitda
Total Operating Expenses
Income Tax Expense
Depreciation And Amortization
Selling General Administrative
Total Revenue
Gross Profit
Cost Of Revenue
Income Before Tax
Total Other Income Expense Net
Selling And Marketing Expenses
Net Income From Continuing Ops
Non Operating Income Net Other
Net Income Applicable To Common Shares
Interest Income
Net Interest Income
Tax Provision
Reconciled Depreciation
Non Recurring
Probability Of Bankruptcy
Understanding current and past EXACT Sciences Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of EXACT Sciences' financial statements are interrelated, with each one affecting the others. For example, an increase in EXACT Sciences' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in EXACT Sciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of EXACT Sciences. Check EXACT Sciences' Beneish M Score to see the likelihood of EXACT Sciences' management manipulating its earnings.
EXACT Sciences Stock Summary
EXACT Sciences competes with Natera, Caredx, Illumina, Twist Bioscience, and Agilent Technologies. Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin. Exact Sciences operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 6420 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
The reason investors look at the income statement is to determine what EXACT Sciences' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining EXACT Sciences's current stock value. Our valuation model uses many indicators to compare EXACT Sciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across EXACT Sciences competition to find correlations between indicators driving EXACT Sciences's intrinsic value. More Info.
EXACT Sciences is rated # 5 in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, EXACT Sciences' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value EXACT Sciences by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
EXACT Sciences Systematic Risk
EXACT Sciences' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. EXACT Sciences volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on EXACT Sciences correlated with the market. If Beta is less than 0 EXACT Sciences generally moves in the opposite direction as compared to the market. If EXACT Sciences Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one EXACT Sciences is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of EXACT Sciences is generally in the same direction as the market. If Beta > 1 EXACT Sciences moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in EXACT Sciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various EXACT Sciences' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of EXACT Sciences growth as a starting point in their analysis.
EXACT Sciences November 22, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of EXACT Sciences help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of EXACT Sciences. We use our internally-developed statistical techniques to arrive at the intrinsic value of EXACT Sciences based on widely used predictive technical indicators. In general, we focus on analyzing EXACT Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build EXACT Sciences's daily price indicators and compare them against related drivers.
When running EXACT Sciences' price analysis, check to measure EXACT Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy EXACT Sciences is operating at the current time. Most of EXACT Sciences' value examination focuses on studying past and present price action to predict the probability of EXACT Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move EXACT Sciences' price. Additionally, you may evaluate how the addition of EXACT Sciences to your portfolios can decrease your overall portfolio volatility.